

Mount Tam Biotechnologies announces TAM-03 a novel compound with potential to treat a range of cancer types

NOVATO, CA - (February 13, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, announces that it will advance a novel 'rapalog', TAM-03, for further development efforts with the ultimate goal of moving TAM-03 into the clinic to treat certain advanced cancers for which current therapies are inadequate. TAM-03 delivers a differentiated mTORC1:2 profile, one that is desirable for treating certain cancers.

"We are excited to bring this compound forward and to begin testing it against a range of cancer types in both *in-vitro* and *in-vivo* pre-clinical studies. Unmet need remains high across a range of cancer types, and a compound like TAM-03 has significant potential to help patients" says Tim Powers, PhD, Chief Scientific Officer of Mount Tam Biotechnologies.

"Rapalogs have been proven effective in treating a range of cancers including advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin and select breast cancers, amongst others. By aiming to improve upon this well understood approach to cancer therapy, we hope to bring a promising therapeutic option into the clinic for these patients" says Mount Tam CEO Richard Marshak.

About Mount Tam Biotechnologies, Inc.

Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Mount Tam is focused on the discovery and development of novel mTOR inhibitors, with specific emphasis to increase levels of mTORC1 inhibition relative to levels of mTORC2 inhibition. Mount Tam believes it has an industry leadership position with the mTOR pathway, and is confident that both TAM-01 and TAM-03 are much more selective mTORC1 inhibitors, with potency to deliver efficacy similar to or great than rapamycin, with selectivity to deliver side effect profiles that are superior to rapamycin with superior PK profiles, that will bring significant benefits to patients suffering from many chronic diseases.

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets are highly target-specific polyketides--a class of compounds with a successful track record with the FDA drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.

Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has already completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE. Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.

For more information visit www.MountTamBiotech.com

Forward-Looking Statements:

The information disclosed in this press release is made as of the date hereof and reflects Mount Tam's most current assessment of its historical position and financial performance. Actual results may differ from those contained herein due to factors outside of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.

These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as "scheduled (future sense)", "intend(s)", "plan(s)", "expect(s)", "believe(s)", "will", "estimate(s)", "anticipate(s)", "expect(s)", "may", "would", "could" or "should" or, in each case, the negative thereof, other variations thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of any such application. Although Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking statements for subsequent events.

Company Contact:

Jim Stapleton
Chief Financial Officer
jim@mounttambiotech.com
Phone: 425-214-4079